BioLineRx (BLRX) FCF Margin (2023 - 2025)
Historic FCF Margin for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to 493.21%.
- BioLineRx's FCF Margin fell 2944400.0% to 493.21% in Q3 2025 from the same period last year, while for Sep 2025 it was 105.93%, marking a year-over-year increase of 343300.0%. This contributed to the annual value of 151.42% for FY2024, which is 3171700.0% up from last year.
- As of Q3 2025, BioLineRx's FCF Margin stood at 493.21%, which was down 2944400.0% from 58.22% recorded in Q2 2025.
- In the past 5 years, BioLineRx's FCF Margin ranged from a high of 115.4% in Q4 2023 and a low of 1182.8% during Q3 2023
- For the 3-year period, BioLineRx's FCF Margin averaged around 418.32%, with its median value being 207.46% (2024).
- In the last 5 years, BioLineRx's FCF Margin skyrocketed by 9840300bps in 2024 and then crashed by -8107200bps in 2025.
- BioLineRx's FCF Margin (Quarter) stood at 115.4% in 2023, then plummeted by -164bps to 73.33% in 2024, then crashed by -573bps to 493.21% in 2025.
- Its FCF Margin stands at 493.21% for Q3 2025, versus 58.22% for Q2 2025 and 1016.08% for Q1 2025.